Recent SEC filings include an amendment to the NeuRX license agreement adjusting the commercial launch and payment commencement to the second half of 2026, with no other material changes.

• On December 28, 2025, Davion Healthcare Plc executed an addendum to its global manufacturing and distribution license agreement with NeuRX Health Inc., revising the commencement date to the second half of 2026 and aligning payment schedules accordingly. No other terms were amended, and the agreement remains in full force and effect [S2].
• The original global license agreement with NeuRX Health Inc., dated October 8, 2025, grants exclusive worldwide rights to manufacture, market, distribute, and sell the BreastCheck product, subject to regulatory approvals and performance obligations [S1].
• NeuRX Health Inc. plans to launch BreastCheck initially in the U.S. in the second half of 2026, with international launches starting in 2027, subject to market conditions [S1].

Davion Healthcare’s unique thermographic technology and intellectual property portfolio position it to capitalize on growing demand for affordable, non-invasive home health monitoring solutions. The global licensing agreement with NeuRX Health Inc. for BreastCheck, with significant license fees and royalties structured over a decade, provides a foundation for future revenue streams. The company’s strategy to expand licensing for additional products across key regions could broaden its market presence. Its capital-efficient model, leveraging third-party manufacturing and distribution, allows focus on innovation and product development. The planned U.S. launch of BreastCheck in the second half of 2026 represents a key commercialization milestone.

The company remains pre-revenue and has incurred operating losses, with limited cash resources and dependence on CEO financial support and future licensee payments for liquidity. Its licensing model exposes it to risks related to licensee performance, regulatory approvals, manufacturing scale-up, and market adoption, which could delay or reduce revenue generation. The absence of large-scale clinical trials for current home-use products may affect market acceptance. The company’s ability to secure additional licensees for other products is uncertain. Transitioning to direct commercialization, if required, could increase costs and operational complexity. Regulatory or competitive challenges could impact its intellectual property protection and market position.

Davion Healthcare’s competitive strengths lie in its proprietary thermographic technology platform, protected by a portfolio of issued patents and pending applications covering its medical non-diagnostic devices and related software. The company’s focus on affordable, non-invasive home-based tests with no known direct competitors utilizing similar technology provides a unique market position. Its licensing-based commercialization model leverages third-party expertise and infrastructure, enabling capital-efficient innovation and market reach. The global exclusive license agreement with NeuRX Health Inc. for the flagship BreastCheck product, including substantial staged license fees and minimum royalties, further supports its competitive positioning. However, the company’s reliance on licensees for regulatory compliance, manufacturing, and commercialization introduces execution risk.

• Licensee Performance and Regulatory Risk: The company’s revenue and growth depend on licensees’ ability to obtain regulatory approvals, manufacture, market, and distribute products successfully. Delays or failures by licensees could materially affect revenues.
• Pre-Revenue Status and Liquidity Risk: Davion Healthcare is pre-revenue with operating losses and limited cash, relying on CEO funding and anticipated licensee payments. Insufficient liquidity could impact operations.
• Intellectual Property Challenges: While the company holds patents and pending applications, there is risk of patent challenges, invalidation, or circumvention that could reduce competitive advantage.
• Market Acceptance and Clinical Validation: The company has not conducted large-scale clinical trials for its home-use products, which may affect customer confidence and regulatory scrutiny.
• Dependence on Key License Agreement: The global license agreement with NeuRX Health Inc. for BreastCheck is critical. Failure of this licensee to meet obligations or commercialize effectively could adversely impact the company.

• Davion Healthcare Plc was incorporated in Cyprus on November 29, 2022, and re-domiciled to Ireland in September 2024, maintaining a Cyprus subsidiary.
• The company focuses on developing and commercializing non-invasive home tests for early detection of health anomalies, using thermographic technology with thermochromic liquid crystal film.
• Davion Healthcare operates a licensing-based commercialization model, designing, developing, and patenting medical products and licensing manufacturing, marketing, sales, and distribution rights to third-party licensees.
• The company retains ownership of intellectual property and provides licensees limited rights to use patents and proprietary know-how for manufacturing and commercialization in defined territories.
• Licensees are responsible for regulatory compliance, manufacturing, marketing, sales, distribution, customer service, warranty administration, and product recalls in their territories.
• Davion Healthcare retains responsibility for product design, regulatory compliance in new territories until licensees are appointed, intellectual property enforcement, and technical support to licensees.
• The company has four completed non-invasive home test products: BreastCheck, FootFlow, Testic, and ThermaDerm.
• BreastCheck and FootFlow have completed Class I medical device self-declaration and registration in initial target markets (USA and Europe) and are commercially prepared for launch.
• Testic and ThermaDerm require only manufacturer’s self-declaration of conformity and registration or notification with regulatory authorities prior to launch.
• The flagship product, BreastCheck, is licensed globally to NeuRX Health Inc. under an agreement amended in December 2025, with staged license fees totaling $120 million and minimum annual royalties of $10 million over ten years.
• NeuRX Health is responsible for regulatory compliance, manufacturing, and commercial distribution of BreastCheck, with an initial U.S. launch planned for the second half of 2026 and international launches starting in 2027.
• Davion Healthcare expects revenue primarily from license fees and royalties based on milestones and sales volumes of licensees.
• The company’s intellectual property portfolio includes issued patents and pending applications covering thermographic medical non-diagnostics, with patent expirations ranging from 2042 to 2044.
• The company has not conducted large-scale randomized clinical trials for the current home-use products but supports performance with internal testing and prototype validation.
• Davion Healthcare is pre-revenue and has incurred operating losses, with net losses of €823,977 in 2025 and €1,320,353 in 2024.
• The company had cash balances of €1,058 at December 31, 2025, and relies on CEO financial support and expected licensee cash flows for liquidity.
• The company’s consolidated financial statements are prepared under IFRS as adopted by the EU, with no reconciliation to U.S. GAAP due to foreign private issuer status.
• The company acquired 100% of Davion Healthcare Corporation (U.S. entity) from its CEO on January 1, 2026, for nominal consideration.
• The company’s licensing agreement with NeuRX includes provisions for termination if payments or obligations are not met.
• The company is actively seeking additional licensees for other products in North America, Europe, and the Middle East under similar licensing structures.
• The company’s board and executives have frozen service fees until Nasdaq listing, with new agreements planned upon listing.
• The company’s financial disclosures emphasize that figures are summarized from SEC filings and provided for informational purposes only.